TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05723965

Intervention type: OTHER
Intervention: As training material for deep learning model.
Description: Using labeled images as training materials for artificial intelligence to develop object detecting model.

Intervention type: OTHER
Intervention: As materials for external validation for the buildup model.
Description: Using the external validation set to evaluate prediction rate and survival outcome.
Study: NCT04082390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RELEASE
Description: Dietary supplement
Study: NCT02161146

Intervention type: DRUG
Group type: OTHER
Intervention: Olopatadine
Description: One drop of olopatadine in the eye on Days 1 and 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine
Description: One drop of olopatadine in the eye on Days 1 and 15.
Study: NCT04082390

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02966249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally
Study: NCT02613117

Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate Gel
Description: Self applied
Study: NCT00639054

Intervention type: PROCEDURE
Intervention: Bone marrow examination
Description: 7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.

Intervention type: PROCEDURE
Intervention: Blood samples
Description: 24 ml of cubital vein blood drawn in addition to diagnostic samples.
Study: NCT03922724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25.
Study: NCT00639054

Intervention type: PROCEDURE
Intervention: Blood samples
Description: 24 ml of cubital vein blood drawn in addition to diagnostic samples.
Study: NCT00523354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
Study: NCT04506554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMVAC + Nivolumab
Description: Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
Study: NCT03922724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOC
Description: e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
Study: NCT01096524

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Physiotherapy
Description: The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab
Description: NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes.
Study: NCT03629067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment T
Description: Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment T
Description: Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment T
Description: Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment R
Description: Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment R
Description: Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment R
Description: Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
Study: NCT01708733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSY
Description: Chinese herbal formula
Study: NCT02461563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg MK-1075
Description: Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg MK-1075
Description: Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg MK-1075
Description: Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg MK-1075
Description: Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study: NCT02966249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally

Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally
Study: NCT03419234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Description: Undergo standard of care surgical castration with bilateral orchiectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orchiectomy
Description: Undergo standard of care surgical castration with bilateral orchiectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study: NCT02613117

Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate Liquid
Description: Professionally Applied

Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: SnF2 Paste
Study: NCT03831191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04378465

Intervention type: OTHER
Intervention: Enhanced Recovery Program (ERP)
Description: An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
Study: NCT02182661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba253BINEB
Study: NCT02356419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin stimulating protein
Description: Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin stimulating protein
Description: Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin stimulating protein
Description: Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin stimulating protein
Description: Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Study: NCT04314765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower third molar extraction
Description: the extraction is performed with one of the two type of flap based non randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower third molar extraction
Description: the extraction is performed with one of the two type of flap based non randomization.
Study: NCT01022957

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic diagnosis
Description: to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
Study: NCT01471028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD treatment
Description: ELAD treatment consists of treatment with an extracorporeal liver assist system.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care (Control)
Description: Control receives standard medical treatment.
Study: NCT00688324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate 333mg, ii tablets PO tid x 2 weeks
Study: NCT00569244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: YAZ flex (SH T00186D)
Description: Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ (SH T00186D)
Description: YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
Study: NCT01175486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actos (Pioglitazone)
Description: Actos 30 mg for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg tid for 6 months
Study: NCT00695955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil with or without add-on chlorthalidone
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil with or without add-on hydrochlorothiazide
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
Study: NCT02106624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nitrogen supply
Description: Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nitrogen supply
Description: Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
Study: NCT03645525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord-derived Mesenchymal stem cell
Description: The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline
Study: NCT03661424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 BATs
Description: A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
Study: NCT01311128

Intervention type: DEVICE
Intervention: T-line hemodynamic monitoring device (placement and use)
Description: The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
Study: NCT03229772

Intervention type: DEVICE
Group type: OTHER
Intervention: Discovery NM/CT 670 CZT Imaging Scan
Description: At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
Study: NCT04243577

Intervention type: DEVICE
Group type: OTHER
Intervention: Tele-EaT Sensors
Description: Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tele-EaT Sensors
Description: Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Sensors
Description: Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Sensors
Description: Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
Study: NCT02172131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03057041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
Study: NCT01961284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zygomatic implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implants and augmentation of maxilla
Study: NCT03626272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
Study: NCT02461563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg MK-1075
Description: Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg MK-1075
Description: Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study: NCT02966249

Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally

Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally
Study: NCT01910610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FOLFIRI-cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mFOLFOX6-bevacizumab
Study: NCT03626272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
Study: NCT01910610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPTIMOX-bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: irinotecan-based chemo + bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XELOX + bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XELOX + bevacizumab
Study: NCT01093807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: 10 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: 20 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 10 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 20 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 10/10 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 10/20 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 20/10 mg once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 20/20 mg once daily for 10 weeks
Study: NCT01566227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: 3 surveys with 10 questions each: one before, during and after treatment
Study: NCT00971854

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Alteration of deep brain stimulator settings
Description: From 130Hz to 60Hz pallidal stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alteration of deep brain stimulator settings
Description: From 130Hz to 60Hz pallidal stimulation